Tumor Suppressor NDRG 2 Tips the Balance of Oncogenic TGF-β Via EMT Inhibition in Colorectal Cancer

L Shen,X Qu,Y Ma,J Zheng,D Chu,B Liu,X Li,M Wang,C Xu,N Liu,L Yao,J Zhang
DOI: https://doi.org/10.1038/oncsis.2013.48
2014-01-01
Oncogenesis
Abstract:Transforming growth factor-beta (TGF-β), a pluripotent cytokine expressed in the colon, has a crucial but paradoxical role in colorectal cancer (CRC). TGF-β is a potent proliferation inhibitor of normal colon epithelial cells and acts as a tumor suppressor. However, TGF-β also promotes invasion and metastasis during late-stage CRC, thereby acting as an oncogene. Thus, understanding the factors behind the paradoxical roles of TGF-β and elucidating the mechanisms by which TGF-β-induced proliferation inhibition is impaired in CRC are necessary. Here, we found that the N-Myc tumor suppressor gene downstream-regulated gene NDRG 2 (N-Myc downstream-regulated gene 2), which is a TGF-β-responsive gene, abrogated TGF-β-induced epithelial–mesenchymal transition (EMT) and further inhibited the invasion and migration of CRC cells. TGF-β positively induced NDRG 2 expression through direct transactivation mediated by Sp1 and by abrogation of the repressive c-Myc/Miz-1 complex on NDRG 2 promoter in normal epithelial cells. Aberrant hypermethylation of NDRG 2, which could respond to TGF-β growth inhibition signaling, abrogated the inhibitory effect of NDRG 2 in TGF-β-induced EMT in CRCs. Reduced NDRG 2 expression was highly correlated with the invasion stage and metastasis of CRC. Our study establishes that NDRG 2 is a new tumor suppressor gene that responds to TGF-β anti-proliferative signaling and tips the balance of oncogenic TGF-β during late-stage CRC.
What problem does this paper attempt to address?